We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TCL:ASXTransurban Group Ltd. Analysis

Data as of 2026-03-10 - not real-time

A$14.11

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Transurban Group trades at a significantly elevated price multiple relative to its peers, with a price‑earnings ratio that far exceeds the industry average, suggesting that the market may be pricing in optimistic growth expectations. The company delivers strong operating margins and a healthy gross margin, yet its payout ratio is well above sustainable levels, raising concerns about the durability of the current dividend yield. A massive debt load relative to equity further stresses the balance sheet, while cash generation remains solid but may be insufficient to comfortably service the leverage.
Technically, the stock sits in a neutral zone: the 20‑day moving average modestly tops the 50‑day average, but both sit below the 200‑day average, and the MACD signals bearish momentum. RSI hovers near the midpoint, and volume is on an upward trend, indicating growing interest but no decisive directional bias. Low beta points to limited price sensitivity to broader market moves, yet the 30‑day volatility is moderate, and regulatory and geographic exposures add layers of risk. The combined picture advises caution, with a preference for holding rather than adding to positions at current levels.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • bearish MACD histogram
  • high price‑earnings multiple
  • increasing trading volume

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • sustainable operating cash flow
  • elevated debt‑to‑equity ratio
  • moderate regulatory environment

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • unsustainable dividend payout
  • overvalued valuation relative to earnings
  • high leverage limiting upside potential

Key Metrics & Analysis

Financial Health

Revenue Growth8.20%
Profit Margin12.19%
P/E Ratio94.1
ROE5.36%
ROA2.08%
Debt/Equity225.12
P/B Ratio5.0
Op. Cash FlowA$1.6B
Free Cash FlowA$570.6M
Industry P/E29.6

Technical Analysis

TrendNeutral
RSI48.7
SupportA$13.69
ResistanceA$14.62
MA 20A$14.17
MA 50A$14.01
MA 200A$14.24
MACDBearish
VolumeIncreasing
Fear & Greed Index80.79

Valuation

Target PriceA$14.20
Upside/Downside0.64%
GradeOvervalued
TypeBlend
Dividend Yield4.82%

Risk Assessment

Beta0.07
Volatility16.92%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.